Skip to content

Clinical study on the treatment of diminished ovarian reserve function (liver and kidney yin deficiency) by tonifying the kidney and filling the essence

Clinical study on the treatment of diminished ovarian reserve function (liver and kidney yin deficiency) by tonifying the kidney and filling the essence

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200061099
Enrollment
Unknown
Registered
2022-06-15
Start date
2022-11-01
Completion date
Unknown
Last updated
2023-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Decreased ovarian reserve function

Interventions

Test group:Herbal supplement for kidney and essence+Fentanyl simulant

Sponsors

Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Meeting the Western diagnostic criteria for DOR; 2. Consistent with the TCM diagnosis of liver and kidney yin deficiency; 3. No pregnancy requirement for the last 3 menstrual cycles; 4. Voluntarily sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Primary or secondary amenorrhea due to congenital abnormalities of the reproductive organs or acquired organic lesions and injuries; 2. Severe primary diseases of the cardiovascular, hepatic, renal and hematopoietic systems; suspected psychiatric patients; patients with diabetes; 3. Bilateral or unilateral oophorectomy; 4. Known or suspected breast cancer; known or suspected precancerous or malignant tumors affected by sex hormones; 5. Acute arterial thromboembolism, active venous thrombosis, thromboembolic disease or history of thromboembolic disease, or risk factors for venous or arterial thrombosis risk factors; 6. Hormone use within the last 2 months; 7. Hypersensitivity to the components of this drug; 8. Severe hypertriglyceridemia; 9. Subjects whose compliance is judged by the investigator to be poor, whose efficacy cannot be judged, or whose data are incomplete, which affects the determination of efficacy

Design outcomes

Primary

MeasureTime frame
Anti-Mullerian hormone;Folliculopoietin;Luteinizing hormone;Estradiol;

Secondary

MeasureTime frame
Chinese Medicine Evidence Scoring Scale;Modified Menopause Kupperman Rating;Hamilton Anxiety Inventory;

Countries

China

Contacts

Public ContactYuxiao Huang

Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine

hyx12386@163.com+86 13581922080

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026